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To analyse predictors of early response after two treat-
ment cycles with Onabotulinumtoxin type A (OnabotA)
in patients with chronic migraine (CM).
Thirty-one patients (24 women, 7 men) with IHS cri-
teria for CM and an inadequate response or intolerance
to other oral preventatives were included. Data regard-
ing the frequency and intensity of headache attacks,
analgesic use and migraine disability assessment scale
(MIDAS) before and after OnabotA treatment was col-
lected; as well as, headache location and the presence of
allodynia or bruxism. The current oral preventive ther-
apy was continued in all patients.
Good responders were patients who after treatment
improved in all of these four categories: headache fre-
quency (CM to low-frequency episodic migraine), head-
pain intensity (reduction of > 75%), analgesic/triptan use
(reduction to a use of two days or less per week), and
disability (from severe to a mild disability measured
using the MIDAS scale). Partial responders were those
who only improved in two of the four categories.
Patients were classified into 3 categories: good respon-
ders (58.1%), partial responders (29%), and non-respon-
ders (12.9%). The age (younger subjects) and the
presence of a shorter migraine history are the two indi-
cators of a better response to the treatment (p = 0.04; p
= 0.04 respectively). Unilateral headache, presence of
allodynia and/or bruxism appears not to be predictors
of response to OnabotA in our study.
Age and the years of migraine history are predictors of
early response to OnabotA in our experience. The
younger the patient and less years of migraine chronifi-
cation are good predictors of early response.
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